BASEL, Switzerland - Roivant Sciences (NASDAQ:ROIV) announced the promising results of the Phase 1b ATMOS study for mosliciguat, a potential first-in-class inhaled therapy for... Roivant (Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback